Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th American Society of Hematology annual meeting
Emmaus will present results of a Phase 3 study of Endari (L-glutamine oral powder) for sickle cell disease treatment at the 59th Annual Meeting of the American Society of Hematology (ASH) taking place in Atlanta, Georgia December 9-12, 2017.
Details of the oral presentation are as follows:
Publication Number: 685
Title: Phase 3 Study of L-glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events
Name: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical II
Date: Monday, December 11, 2017
Time: 2:45 PM – 4:15 PM
Room: Georgia World Congress Center, Building B, Level 3, B308-B309
+myBinderRelated Content
-
Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French...Patients with sickle cell disease (SCD) ...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
-
Guideline Information for PatientsLiving with chronic pain can be devastat...
-
My Red Cell Exchangehttps://www.youtube.com/watch?v=HTcLwgLE...
-
California Institute For Regenerative Medicine Awards City Of Hope $5.74 Million For Severe Sickle Cell Disease Clin...The California Institute for Regenerativ...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Statement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.